A groundbreaking study sheds light on the effectiveness of steroids in treating a severe brain condition, HSV encephalitis, but the results are not what you'd expect. Do steroids really make a difference?
A large-scale clinical trial in the UK aimed to clarify the role of the steroid dexamethasone in managing this life-altering brain inflammation. The study, DexEnceph, was a collaborative effort led by The Pandemic Institute, University of Liverpool, and Walton Centre NHS Foundation Trust, along with Encephalitis International and researchers across the country.
HSV encephalitis, caused by the herpes simplex virus, is the most prevalent form of sporadic viral encephalitis globally. While the antiviral drug aciclovir has significantly improved survival rates since the 1970s, many survivors struggle with long-term cognitive issues, particularly memory problems.
The DexEnceph study, funded by the Efficacy and Mechanism Evaluation (EME) Programme, a joint initiative of the National Institute for Health and Care Research (NIHR) and the UKRI Medical Research Council (MRC), sought to determine if adding dexamethasone to aciclovir treatment would enhance long-term outcomes.
In this phase 3 trial, 94 patients from 53 NHS hospitals were randomly assigned to receive either dexamethasone plus aciclovir or aciclovir alone. The primary focus was on verbal memory at 26 weeks, measured by the Wechsler Memory Scale. Surprisingly, the results revealed no significant overall difference between the two groups.
But here's where it gets interesting: when steroids were administered earlier in the illness, patients tended to recover better. And the study confirmed that dexamethasone is safe for patients with HSV encephalitis.
Corticosteroids are already a go-to treatment for other inflammatory brain diseases, such as autoimmune encephalitis. The fact that dexamethasone is safe in HSV encephalitis opens up a new avenue for treatment. Should it be given to all patients with suspected encephalitis, even before the cause is known?
Professor Tom Solomon CBE, leading the DexEnceph study, highlights the long-standing debate: "Corticosteroids have been a topic of controversy in HSV encephalitis due to their potential benefits and immunosuppressive risks. This study provides clarity, showing that early steroid use is safe and may even improve outcomes."
Dr. Ava Easton, Chief Executive of Encephalitis International, emphasizes the impact: "This trial is a significant milestone, offering clear guidance on what works and what doesn't. It's a relief to finally answer a question that has perplexed clinicians for years."
Dr. Mark Ellul, a neurologist and clinical lecturer, adds, "HSV encephalitis is a critical condition, and DexEnceph provides much-needed evidence for early treatment decisions. The study also demonstrates the power of national collaboration in conducting high-quality research in acute neurological emergencies."
So, do steroids have a place in HSV encephalitis treatment? The study suggests a nuanced approach, and the medical community is now better equipped to make informed decisions.
